A family of psychedelic compounds licensed to Clearmind Medicine now has pending patent applications, including those in mainland China, at the European Patent Office and, as of a publication Clearmind announced on November 19, in Hong Kong. Across Clearmind’s SEC filings and press releases, the patent record and ClinicalTrials.gov, the drug program behind those filings has no disclosed lead candidate, development code, laboratory or animal data, regulatory meeting, investigational new drug application or registered human trial.

The license under which Clearmind holds the compounds explains the gap. Its development plan, prepared by Clearmind and approved by Yissum, appears in the license filed with the U.S. Securities and Exchange Commission. It schedules the first human study for the seventh or eighth year of the agreement, which, counted from the stated effective date, falls between roughly 2030 and early 2032.

Neither fact is unusual on its own. Drug developers routinely carry patent applications into foreign jurisdictions years before a compound is tested in people, because the deadlines for entering each country are set by patent law, counted from the first filing, not by progress in the lab. What the two facts show together is narrower: each new patent announcement in this family tells readers about legal optionality. None of them has told readers that a drug has moved closer to the clinic.

What Clearmind holds, and what Yissum owns

The patent family belongs to Yissum Research Development Company, the technology-transfer company of the Hebrew University of Jerusalem. The inventors are Hebrew University researchers Ahmad Masarwa, Rami Yaka and Avi Priel. Clearmind, a Vancouver-based company listed on Nasdaq, holds an exclusive, worldwide, sublicensable license to develop and sell products under them.

The license, filed as an exhibit to Clearmind’s annual report in January 2025, sets out what that means in practice:

  • Ownership. The license requires every application to be filed in Yissum’s name. Yissum runs prosecution in consultation with Clearmind, and Clearmind pays the costs.
  • Payments. A 3 percent royalty on net sales; annual maintenance fees of $25,000 rising to $50,000 that begin on the agreement’s fifth anniversary; $400,000 when the first patient enrolls in a Phase 3 trial and $600,000 on the first commercial sale in the U.S. or EU; and 20 percent of any sublicense income.
  • Diligence. Yissum may terminate if Clearmind falls more than 60 days behind the development milestones, after which the patent rights revert to Yissum.

Clearmind therefore owns the right to develop and commercialize these compounds, on terms that keep the underlying intellectual property with the university.

The timetable in the contract

The Yissum license attaches a development plan that Clearmind prepared and Yissum approved. Behavioral Wire has translated its year numbers into calendar dates from the agreement’s stated effective date, March 31, 2024:

  • First 24 months, to about March 2026: small-scale synthesis of the active compound.
  • Year 3, about April 2026 to March 2027: define how the compounds activate the 5-HT2A serotonin receptor in laboratory assays.
  • Year 4: the same work in animals.
  • Years 5 and 6, about 2028 to 2030: a pre-IND meeting with regulators, IND-enabling studies, manufacturing to clinical standards and the IND submission itself.
  • Years 7 and 8, about 2030 to early 2032: pending IND approval, the start of a Phase 1 study.

The plan can be changed with Yissum’s written approval, and the identical timetable appears in a second Yissum license Clearmind signed the same month for a different compound. It reads as a standard contractual schedule, not a forecast specific to these molecules. It remains the only public statement of when this program is expected to reach people, and Clearmind has not reported progress against it.

What the patent itself contains

The international application, published in March 2025, claims two general formulas of synthetic compounds, which it describes as psychedelic, along with compositions containing them and their use in three conditions: depression including treatment-resistant depression, “stress including PTSD,” and cerebral ischemia, a shortage of blood flow to the brain. PTSD is one of three claimed uses, though Clearmind’s announcements have presented the family as a PTSD program.

The published specification’s worked examples are chemistry: the synthesis of two halogenated tryptamines and a third compound, with their spectroscopic characterization. It reports no receptor, animal or other biological results. A January 2023 Clearmind release said the underlying Hebrew University project had included work in an animal model; those results have not been published. The application’s abstract also describes the compounds as having “psychedelic bioactivity,” while Clearmind presents its lead program, CMND-100, as non-hallucinogenic. Whether these compounds produce hallucinogenic effects has not been disclosed.

From Jerusalem to Hong Kong

The family’s public record runs as follows:

  • September 2023: U.S. provisional application filed, the family’s priority date.
  • March 2024: license agreement with Yissum.
  • September 2024: international application filed under the Patent Cooperation Treaty.
  • March 2025: international application published.
  • April 2026: mainland China application published, now pending.
  • July 2026: European application published, now pending.
  • July 20, 2026: Clearmind announces a Hong Kong filing.
  • November 19, 2026: Clearmind announces the publication of a Hong Kong patent application for the family.

The November 19 event is a publication, not a grant. Hong Kong runs its own patent system, separate from mainland China’s, and a Hong Kong patent has effect only in Hong Kong. A standard patent there is granted either after Hong Kong’s own examination or by re-registering a patent first granted by a designated office, which includes China’s national patent office. On the second route, Hong Kong does not examine the invention itself and grants only once the designated office has. That structure lets an applicant with an application pending at a designated office extend protection to a separate territory without a second examination. Clearmind’s announcements do not say which route its Hong Kong application takes.

Hong Kong is a repeat destination for Clearmind. Before this family, it announced a Hong Kong grant in June 2024 for a binge-behavior patent covering its lead compound, MEAI, and in March 2026 a Hong Kong filing for an MEAI combination for depression and the publication of six Hong Kong patents for psychedelic combination therapies.

Its filings describe no operations there. The annual report for the year to October 2025 names its operating subsidiaries as companies in Israel and Canada and does not mention Hong Kong or Asia, and no Hong Kong clinical partner, contract research organization, distributor, regulatory filing or licensing discussion has been disclosed. When it announced the filing in July, Clearmind called Hong Kong “a strategic gateway for regional market access.” A patent there does not authorize a clinical trial, approve a drug, provide protection in mainland China or grant distribution rights. It secures the option to stop others from making, using or selling the claimed compounds in Hong Kong, if a patent is granted.

What the record shows

Clearmind’s clinical activity sits elsewhere. Its first-in-human study of CMND-100, in healthy volunteers and people with alcohol use disorder, is recruiting, and the company announced full enrollment of the study’s Part C on November 16. ClinicalTrials.gov lists it as Clearmind Medicine’s only registered study. The company ended July with $12.0 million in cash and cash equivalents after using $5.8 million in operations over the nine months to July; its interim financial statements carry going-concern language, while management says that cash covers at least the next 12 months.

For the PTSD compounds, the public record now contains a growing map of pending patent applications and a contractual timetable that does not reach human testing until the end of the decade. Investors reading the next announcement from this family can ask a simple question of it: does it describe new territory, or a new result?